Next-Gen Gene Therapy Firm Kate Therapeutics Starts Out With Big Pharma Partner

Announces $51m Series A, License Deal With Astellas

 
• By Joseph Haas and Lisa Takagi
Adenovirus
Kate Therapeutics focuses on novel AAV vectors with smaller payloads • Source: Shutterstock

More from Start-Ups & SMEs

More from Business